PMC6069027_01
Patient lesion: progression over time. (A) Lesion prior to treatment in November. (B) Lesion post third infusion of nivolumab in December. (C) Lesion post surgery in February. (D) Lesion post ninth infusion of nivolumab in March.
10.1177_2324709618786319-fig2.jpg
PMC6069027_01_10.1177_2324709618786319-fig2.jpg
fig2-2324709618786319
Over the next few weeks, treatment with nivolumab resulted in significant shrinkage of the residual tumor, as shown in Figure 2.
PMC6069027_02
PMC6069027_03
Invasion of the tumor at the level of T5.
10.1177_2324709618786319-fig3.jpg
PMC6069027_03_10.1177_2324709618786319-fig3.jpg
fig3-2324709618786319
Her second 12-week restaging scan demonstrated significant growth of the paraspinal thoracic mass with apparent encroachment of the spinal canal at the level of T5 even while the rest of her lesions continued to diminish in size (Figure 3).